Product/Composition:- | Thalidomide |
---|---|
Strength:- | 50 mg, 100 mg, 150 mg , 200 mg |
Form:- | Capsules |
Reference Brands:- | Thalomid®(US), Thalidomide Celgene(EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
halidomide is an oral immunomodulatory drug approved for multiple myeloma and erythema nodosum leprosum (ENL) in the US and EU. Available as Thalomid® in the US and Thalidomide Celgene in the EU, it comes in 50 mg, 100 mg, 150 mg, and 200 mg capsules. Known for its anti-angiogenic properties, it’s used in combination therapy for oncology. Due to teratogenic risks, distribution is regulated. Ideal for B2B pharma seeking oncology portfolio expansion, licensing, or API sourcing in global markets.
Thalidomide is an oral immunomodulatory drug (IMiD) approved in the US and EU for treating multiple myeloma and erythema nodosum leprosum (ENL). Marketed as Thalomid® in the US and Thalidomide Celgene in the EU, it is available in 50 mg, 100 mg, 150 mg, and 200 mg capsule strengths. With anti-angiogenic and anti-inflammatory properties, thalidomide is a key oncology asset in combination therapy. Due to its teratogenic risks, distribution is strictly regulated under REMS and controlled access programs. Ideal for B2B pharmaceutical companies seeking oncology portfolio expansion, licensing, or GMP-compliant API and finished formulation sourcing in global markets.
Embrace a platform that empowers you to invest in gold online effortlessly, making the path to financial growth accessible to everyone.
Get access to the finest pharmacy products with a NazarethPharmacy.com. They offer comprehensive worldwide pharmacy services, making them your best choice for online medications